Cargando…

Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus

The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobac...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Hiroaki, Sakakibara, Yumi, Sakata, Ayumi, Kurashige, Rie, Murakami, Daisuke, Kageshima, Hiroki, Saito, Akira, Miyazaki, Yasunari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538184/
https://www.ncbi.nlm.nih.gov/pubmed/31136634
http://dx.doi.org/10.1371/journal.pone.0217504
_version_ 1783422148968185856
author Saito, Hiroaki
Sakakibara, Yumi
Sakata, Ayumi
Kurashige, Rie
Murakami, Daisuke
Kageshima, Hiroki
Saito, Akira
Miyazaki, Yasunari
author_facet Saito, Hiroaki
Sakakibara, Yumi
Sakata, Ayumi
Kurashige, Rie
Murakami, Daisuke
Kageshima, Hiroki
Saito, Akira
Miyazaki, Yasunari
author_sort Saito, Hiroaki
collection PubMed
description The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA), which should resolve the problem of antibiotic-resistant bacteria. Bactericidal tests showed that LYZOX killed 50% more P. aeruginosa (NBRC 13275), A. baumannii and MRSA than the control treatment after 60 min. In addition, LYZOX was shown to inhibit the growth of P. aeruginosa (NBRC 13275 and PAO1), A. baumannii and MRSA better than its components. To elucidate the antibacterial mechanism of LYZOX, we performed cell membrane integrity assays, N-phenyl-1-naphthylamine assays, 2-nitrophenyl β-D-galactopyranoside assays and confocal laser scanning microscopy. These results showed that LYZOX affected bacterial cell walls and increased the permeability of the outer membrane and the plasma membrane. Furthermore, each type of bacteria treated with LYZOX was observed by electron microscopy. Electron micrographs revealed that these bacteria had the morphological features of both lysozyme-treated and chitosan oligosaccharide-treated bacteria and that LYZOX destroyed bacterial cell walls, which caused the release of intracellular contents from cells. An acquired drug resistance test revealed that these bacteria were not able to acquire resistance to LYZOX. The hemolytic toxicity test demonstrated the low hemolytic activity of LYZOX. In conclusion, LYZOX exhibited antibacterial activity and low drug resistance in the presence of P. aeruginosa, A. baumannii and MRSA and showed low hemolytic toxicity. LYZOX affected bacterial membranes, leading to membrane disruption and the release of intracellular contents and consequent bacterial cell death. LYZOX may serve as a novel candidate drug that could be used for the control of refractory infections.
format Online
Article
Text
id pubmed-6538184
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65381842019-06-05 Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus Saito, Hiroaki Sakakibara, Yumi Sakata, Ayumi Kurashige, Rie Murakami, Daisuke Kageshima, Hiroki Saito, Akira Miyazaki, Yasunari PLoS One Research Article The recent emergence of antibiotic-resistant bacteria requires the development of new antibiotics or new agents capable of enhancing antibiotic activity. This study evaluated the antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA), which should resolve the problem of antibiotic-resistant bacteria. Bactericidal tests showed that LYZOX killed 50% more P. aeruginosa (NBRC 13275), A. baumannii and MRSA than the control treatment after 60 min. In addition, LYZOX was shown to inhibit the growth of P. aeruginosa (NBRC 13275 and PAO1), A. baumannii and MRSA better than its components. To elucidate the antibacterial mechanism of LYZOX, we performed cell membrane integrity assays, N-phenyl-1-naphthylamine assays, 2-nitrophenyl β-D-galactopyranoside assays and confocal laser scanning microscopy. These results showed that LYZOX affected bacterial cell walls and increased the permeability of the outer membrane and the plasma membrane. Furthermore, each type of bacteria treated with LYZOX was observed by electron microscopy. Electron micrographs revealed that these bacteria had the morphological features of both lysozyme-treated and chitosan oligosaccharide-treated bacteria and that LYZOX destroyed bacterial cell walls, which caused the release of intracellular contents from cells. An acquired drug resistance test revealed that these bacteria were not able to acquire resistance to LYZOX. The hemolytic toxicity test demonstrated the low hemolytic activity of LYZOX. In conclusion, LYZOX exhibited antibacterial activity and low drug resistance in the presence of P. aeruginosa, A. baumannii and MRSA and showed low hemolytic toxicity. LYZOX affected bacterial membranes, leading to membrane disruption and the release of intracellular contents and consequent bacterial cell death. LYZOX may serve as a novel candidate drug that could be used for the control of refractory infections. Public Library of Science 2019-05-28 /pmc/articles/PMC6538184/ /pubmed/31136634 http://dx.doi.org/10.1371/journal.pone.0217504 Text en © 2019 Saito et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Saito, Hiroaki
Sakakibara, Yumi
Sakata, Ayumi
Kurashige, Rie
Murakami, Daisuke
Kageshima, Hiroki
Saito, Akira
Miyazaki, Yasunari
Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
title Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
title_full Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
title_fullStr Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
title_full_unstemmed Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
title_short Antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (LYZOX) against Pseudomonas aeruginosa, Acinetobacter baumannii and Methicillin-resistant Staphylococcus aureus
title_sort antibacterial activity of lysozyme-chitosan oligosaccharide conjugates (lyzox) against pseudomonas aeruginosa, acinetobacter baumannii and methicillin-resistant staphylococcus aureus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6538184/
https://www.ncbi.nlm.nih.gov/pubmed/31136634
http://dx.doi.org/10.1371/journal.pone.0217504
work_keys_str_mv AT saitohiroaki antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT sakakibarayumi antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT sakataayumi antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT kurashigerie antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT murakamidaisuke antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT kageshimahiroki antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT saitoakira antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus
AT miyazakiyasunari antibacterialactivityoflysozymechitosanoligosaccharideconjugateslyzoxagainstpseudomonasaeruginosaacinetobacterbaumanniiandmethicillinresistantstaphylococcusaureus